文献

主要文献

• Ang, K.H., Thura M., Tan, Q.S.W., Gupta, A., Kuan, K.Y., Li, J., Chia, P.L.,, Qiu, B., Hong, J.M.,Guo, K., Wang, X., Su, X., Zeng, Q., (2025) PRL3-zumab as an anti-angiogenic therapy in neovascular eye diseases. Nature Communications 4791 (2025).
• Park, D.J. Thura M., Chiu, V.K., Vicuna B., Ang, K.H., Sanchez B., Chia, P.L., Kuan, K.Y., Li, J., Zhang, K., Zheng, W.H., Ng, M.C.H., and Zeng, Q., (2025) The PRL3-zumab paradigm: A multicenter, single-dose-level phase 2 basket clinical trial design of an unconventional cancer immunotherapy. Cell Reports Medicine (102-120.
• Loh, A.H.P., Thura M., Gupta, A., Tan, S.H., Kuan, K. K. Y., Ang, K.W., Merchant, K., Chang, K.T.E., Yon, H.Y., Chen, Y., Cheng, M. H.W., Mahadev, A., Ng, M.C.H., Seng, M.S-F., Lyer,P., Chia, P.L., Soh, S.Y., and Zeng,Q., (2023) Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody. Molecular Therapy Oncolytics 30 (153-166).
• Chee, C.E., Ooi. M., Lee, SC., Sundar, R., Heong, V., Yong, WP., Ng, C.H., Wong, A., Lim, J.S.J., Tan, D. S. P., Soo, R., Tan, J.T.C., Yang, S., Thura, M., Al-Aidaroos, A. Q., Chng, W. J., Zeng, Q., Boon-Cher Goh, BC. (2023) A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies. Targeted Oncology 18(2).

• 1
• 2
• 3
• …
• 8